Fluticasone propionate: Pharmacology and implications for clinical practice

Advances in Therapy

Volumn 14, Issue 4, 1997, Pages 153-159

  Handing, Stuart M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Beclomethasone dipropionate; Budesonide; Corticosteroid; Dexamethasone; Fluticasone propionate; Triamcinolone acetonide

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LIPOPHILICITY; MAST CELL DEGRANULATION; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; PROPHYLAXIS; RECEPTOR AFFINITY; TOPICAL DRUG ADMINISTRATION;

EID: 0030882924     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Tse CST, Bernstein IL. Corticosteroid aerosols in the treatment of asthma. Pharnmcotherapy. 1984; 4:334-342.
2. Brattsand R, Thalén A, Roempke K, Källström L, Gruvstad E. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis. 1982;63(suppl 122):62-73.
3. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990;84(suppl A):19-23.
4. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332:868-875.
5. Busse WW. What role for inhaled steroids in chronic asthma? Chest. 1993;104:1565-1571.